Condition: HER2 Negative · Low PD-L1 Expressing · Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma · Sponsor: Qilu Hospital of Shandong University
This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma
This description comes directly from the study's public registry record.
Lian Liu, MD, PHD · 0531-82169851 · tounao@126.com
Song Li, MD, PHD · 0531-82169851
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Binzhou Medical University Hospital | Binzhou, Shandong, China | Recruiting |
| Dezhou People's Hospital | Dezhou, Shandong, China | Recruiting |
| Shengli Oilfield Central Hospital | Dongying, Shandong, China | Recruiting |
| Qilu Hospital of Shandong University | Jinan, Shandong, China | Recruiting |
| Shandong Provincial Hospital Affiliated to Shandong First Medical University | Jinan, Shandong, China | Recruiting |
| Shandong Provincial Third Hospital | Jinan, Shandong, China | Recruiting |
| Jinan Central Hospital | Jinan, Shandong, China | Recruiting |
| Jinan Third People's Hospital | Jinan, Shandong, China | Recruiting |
| Shandong Qianfoshan Hospital | Jinan, Shandong, China | Recruiting |
| Affiliated Hospital of Jining Medical College | Jining, Shandong, China | Recruiting |
| Liaocheng People's Hospital | Liaocheng, Shandong, China | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06932068